| Q30445038 | A possible anti-inflammatory role of angiotensin II type 2 receptor in immune-mediated glomerulonephritis during type 1 receptor blockade |
| Q46779292 | ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats |
| Q46034067 | ANG II-AT1 receptor pathway is involved in the anti-fibrotic effect of beta-elemene. |
| Q44532186 | AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4). |
| Q44041359 | Accelerated reversal of carbon tetrachloride-induced cirrhosis in rats by the endothelin receptor antagonist TAK-044. |
| Q54765190 | Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. |
| Q35437089 | Activation of the renin-angiotensin system stimulates biliary hyperplasia during cholestasis induced by extrahepatic bile duct ligation |
| Q45190324 | Administration of ANG II induces iron deposition and upregulation of TGF-beta1 mRNA in the rat liver |
| Q42795515 | Administration of Granulocyte Colony-Stimulating Factor Ameliorates Radiation-Induced Hepatic Fibrosis in Mice |
| Q43263326 | An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells |
| Q42176947 | Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. |
| Q43015011 | Angiotensin II increases mRNA levels of all TGF-beta isoforms in quiescent and activated rat hepatic stellate cells. |
| Q40419536 | Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression |
| Q43088280 | Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse |
| Q34769458 | Angiotensin II type 1 receptor antagonist attenuates lacrimal gland, lung, and liver fibrosis in a murine model of chronic graft-versus-host disease |
| Q47272307 | Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis |
| Q80368658 | Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis |
| Q41825863 | Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats |
| Q38129544 | Angiotensin blockade does not affect fibrosis progression in recurrent hepatitis C after liver transplantation |
| Q36808001 | Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis |
| Q37313049 | Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option? |
| Q36526062 | Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice |
| Q35766650 | Angiotensinogen promoter polymorphisms predict low diffusing capacity in U.S. and Spanish IPF cohorts |
| Q35105721 | Approaches for treatment of liver fibrosis in chronic hepatitis C |
| Q46213897 | Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver |
| Q37175512 | Autocrine regulation of biliary pathology by activated cholangiocytes |
| Q52661962 | Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. |
| Q90680432 | Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats |
| Q36849068 | Blockade of renin-angiotensin system in antifibrotic therapy |
| Q24675332 | CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells |
| Q33581421 | CD38-mediated Ca2+ signaling contributes to angiotensin II-induced activation of hepatic stellate cells: attenuation of hepatic fibrosis by CD38 ablation |
| Q41663953 | Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats |
| Q91900498 | Carvedilol Inhibits Angiotensin II-Induced Proliferation and Contraction in Hepatic Stellate Cells through the RhoA/Rho-Kinase Pathway |
| Q42252132 | Cellular and molecular mechanisms of intestinal fibrosis |
| Q54688272 | Changes in the expression of angiotensin II type 1 receptor in the development of liver fibrosis. |
| Q47993417 | Changes of angiotensin-converting enzyme activity in the pancreas of chronic hypoxia and acute pancreatitis |
| Q51485787 | Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. |
| Q46164230 | Chronic treatment with angiotensin AT1 receptor antagonists reduced serum but not bone TGF-beta1 levels in ovariectomized rats |
| Q52668406 | Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis. |
| Q42971866 | Chymase inhibition attenuates tetrachloride-induced liver fibrosis in hamsters |
| Q46924848 | Chymase inhibitor ameliorates hepatic steatosis and fibrosis on established non-alcoholic steatohepatitis in hamsters fed a methionine- and choline-deficient diet |
| Q45255383 | Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development. |
| Q39320160 | Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. |
| Q39775863 | Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats |
| Q38088855 | Combinatorial use of single nucleotide polymorphisms to help predict liver fibrosis in patients with hepatitis C infections. |
| Q45861165 | Combined Local Pulmonary and Systemic Delivery of AT2R Gene by Modified TAT Peptide Nanoparticles Attenuates Both Murine and Human Lung Carcinoma Xenografts in Mice. |
| Q48886971 | Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis. |
| Q53149405 | Comparative study of three angiotensin II type 1 receptor antagonists in preventing liver fibrosis in diabetic rats: stereology, histopathology, and electron microscopy. |
| Q43826988 | Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis |
| Q41832154 | Current and novel therapies for the treatment of nonalcoholic steatohepatitis |
| Q41372298 | DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis |
| Q28286911 | Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats |
| Q39459741 | Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. |
| Q39517819 | Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis. |
| Q36853076 | Effect of Antiviral Therapy on Serum Activity of Angiotensin Converting Enzyme in Patients with Chronic Hepatitis C. |
| Q53531054 | Effect of angiotensin-converting enzyme inhibition on experimental hepatic fibrogenesis. |
| Q52688162 | Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. |
| Q43206635 | Effect of compound rhodiola sachalinensis A Bor on CCl4-induced liver fibrosis in rats and its probable molecular mechanisms |
| Q45169698 | Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats |
| Q33840207 | Effect of non-alcoholic liver disease on recurrence rate and liver regeneration after liver resection for colorectal liver metastases |
| Q28568734 | Effect of phorbol ester and platelet-derived growth factor on protein kinase C in rat hepatic stellate cells |
| Q41110019 | Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model |
| Q84785198 | Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial |
| Q36410515 | Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection |
| Q31158693 | Effects of Chinese traditional compound, JinSanE, on expression of TGF-beta1 and TGF-beta1 type II receptor mRNA, Smad3 and Smad7 on experimental hepatic fibrosis in vivo |
| Q33232137 | Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells |
| Q92798645 | Effects of losartan and atorvastatin on the development of early posttraumatic joint stiffness in a rat model |
| Q54590269 | Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats. |
| Q36503291 | Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study |
| Q30842488 | Effects of the tyrosine protein kinase inhibitor genistein on the proliferation, activation of cultured rat hepatic stellate cells |
| Q35919778 | Endogenous hydrogen sulfide is associated with angiotensin II type 1 receptor in a rat model of carbon tetrachloride-induced hepatic fibrosis |
| Q27023122 | Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress |
| Q41990004 | Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice |
| Q81164980 | Examination of changes in TGF-beta1 and KL-6 expression over time in patients with chronic hepatitis C by AT-II receptor blocker therapy |
| Q80094000 | Expression of angiotensin II receptor type 1 is reduced in advanced rat liver fibrosis |
| Q26780248 | Genetic background in nonalcoholic fatty liver disease: A comprehensive review |
| Q34646183 | Genetic determinants of hepatic steatosis in man. |
| Q37926957 | Genetic variants in candidate genes influencing NAFLD progression |
| Q44927708 | Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. |
| Q44225009 | Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension |
| Q36387949 | Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis |
| Q22305506 | Hepatic steatosis: a benign disease or a silent killer |
| Q26771518 | Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step |
| Q43293073 | High expression of angiotensin-converting enzyme and angiotensin-converting enzyme 2 in preservation injury after liver transplantation in rats |
| Q43255184 | Highly purified eicosapentaenoic acid ethyl ester prevents development of steatosis and hepatic fibrosis in rats |
| Q35029422 | Hybrid formation between the intracellular faces of the bradykinin B2 and angiotensin II AT1 receptors and signal transduction. |
| Q37428940 | Hyperoxia downregulates angiotensin-converting enzyme-2 in human fetal lung fibroblasts |
| Q34608817 | Hypertension and fatty liver: guilty by association? |
| Q46608132 | Impact of Olmesartan Medoxomil on Amiodarone-Induced Pulmonary Toxicity in Rats: Focus on Transforming Growth Factor-ß1. |
| Q46003911 | Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C. |
| Q34218427 | Ingredients of Huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway |
| Q44036823 | Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. |
| Q33788174 | Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis |
| Q33866293 | Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C. |
| Q100395381 | Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications |
| Q43246095 | Involvement of mast cell chymase in burn wound healing in hamsters |
| Q39879822 | Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats. |
| Q92699452 | Irbesartan Ameliorates Lipid Deposition by Enhancing Autophagy via PKC/AMPK/ULK1 Axis in Free Fatty Acid Induced Hepatocytes |
| Q37283801 | JunD and HIF-1alpha mediate transcriptional activation of angiotensinogen by TGF-beta1 in human lung fibroblasts |
| Q39834604 | Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells |
| Q64902768 | Liver and Steroid Hormones—Can a Touch of p53 Make a Difference? |
| Q37772958 | Liver regeneration and tumour stimulation: implications of the renin-angiotensin system. |
| Q37779281 | Local RAS. |
| Q40981994 | Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis |
| Q36924883 | Losartan may inhibit the progression of liver fibrosis in chronic HCV patients |
| Q35744613 | Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats |
| Q36852793 | Matrix metalloproteinase gene delivery for liver fibrosis |
| Q37886792 | Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease |
| Q50723328 | Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats. |
| Q46102659 | Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid |
| Q33694464 | Myogenic lineage differentiated mesenchymal stem cells enhance recovery from dextran sulfate sodium-induced colitis in the rat. |
| Q90028399 | NADPH Oxidase Inhibition in Fibrotic Pathologies |
| Q36410552 | New treatments for nonalcoholic fatty liver disease |
| Q37381178 | Non-alcoholic steatohepatitis: an overview |
| Q37699734 | Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment |
| Q37681360 | Nonalcoholic fatty liver disease: a review and update |
| Q37982811 | Novel anti-fibrotic modalities for liver fibrosis: molecular targeting and regenerative medicine in fibrosis therapy |
| Q55449343 | Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model. |
| Q36179902 | Pathogenesis and management issues for non-alcoholic fatty liver disease |
| Q47891348 | Periostin cross‑reacts with the renin‑angiotensin system during liver fibrosis development. |
| Q36936358 | Present and future therapeutic strategies in non-alcoholic fatty liver disease |
| Q46255340 | Prevention and treatment of Schistosoma mansoni-induced liver fibrosis in mice |
| Q53588998 | Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. |
| Q37025968 | Prior hypoxia prevents downregulation of ACE-2 by hyperoxia in fetal human lung fibroblasts |
| Q53910016 | Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. |
| Q36257966 | Protective effects of angiotensin II interruption: evidence for antiinflammatory actions |
| Q37100243 | Protective role of angiotensin II type 2 receptor signaling in a mouse model of pancreatic fibrosis |
| Q34731373 | Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. |
| Q39360840 | Renin angiotensin system in liver diseases: Friend or foe? |
| Q89640256 | Renin-angiotensin inhibitors were associated with improving outcomes of hepatocellular carcinoma with primary hypertension after hepatectomy |
| Q79345593 | Renin-angiotensin system and progression of chronic liver diseases |
| Q37507825 | Renin-angiotensin system in the pathogenesis of liver fibrosis |
| Q36360551 | Review article: Drug therapy for non-alcoholic fatty liver disease |
| Q37183154 | Review article: diagnosis and treatment of non-alcoholic fatty liver disease |
| Q33632736 | Role of NADPH oxidases in liver fibrosis |
| Q36456025 | Salvianolic Acid B Attenuates Rat Hepatic Fibrosis via Downregulating Angiotensin II Signaling |
| Q42695116 | Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B. |
| Q51744902 | Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantation. |
| Q39177106 | Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease |
| Q34618881 | Susceptibility and gene interaction study of the angiotensin II type 1 receptor (AGTR1) gene polymorphisms with non-alcoholic fatty liver disease in a multi-ethnic population |
| Q43933934 | Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma |
| Q42591676 | Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy. |
| Q47863448 | Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. |
| Q37139937 | Targeting tissue angiotensin-converting enzyme for imaging cardiopulmonary fibrosis |
| Q83611006 | Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma |
| Q37071406 | Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection |
| Q80101963 | Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats |
| Q53058328 | Tetramethylpyrazine inhibits angiotensin II-induced activation of hepatic stellate cells associated with interference of platelet-derived growth factor β receptor pathways. |
| Q39740192 | The Cooperative Effect of Local Angiotensin-II in Liver with Adriamycin Hepatotoxicity on Mitochondria. |
| Q91715276 | The Modulatory Action of Vitamin D on the Renin-Angiotensin System and the Determination of Hepatic Insulin Resistance |
| Q26766479 | The Role of NADPH Oxidases (NOXs) in Liver Fibrosis and the Activation of Myofibroblasts |
| Q35124395 | The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort. |
| Q37218569 | The renin-angiotensin system and malignancy |
| Q37867350 | The role of the renin-angiotensin system in liver fibrosis |
| Q40743246 | Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis |
| Q45070082 | Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis |
| Q48453485 | Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium |
| Q28476698 | Towards a system level understanding of non-model organisms sampled from the environment: a network biology approach |
| Q39150702 | Transgenic expression of human neutrophil peptide-1 enhances hepatic fibrosis in mice fed a choline-deficient, L-amino acid-defined diet |
| Q37847181 | Treatment of non-alcoholic fatty liver disease with focus on emerging drugs |
| Q55460608 | Treatment options for nonalcoholic fatty liver disease. |
| Q36304115 | Treatment strategies in nonalcoholic fatty liver disease |
| Q44111246 | Up-regulation of components of the renin-angiotensin system in liver fibrosis in the rat induced by CCL₄. |
| Q38006726 | Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. |
| Q47106953 | Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma |
| Q41933963 | Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis |
| Q73534640 | [Fibrogenesis and liver transplantation] |